Porat Ruth purchased $51K of BX

Porat Ruth purchased 371 shares of Blackstone Inc. (BX) at an average of $137.17 ($137.10–$137.32) across 2 trades on 2026-08-10.

Original reporting
SEC EDGAR · Porat Ruth
Published Aug 12, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BX
Bullish
medium confidence
Mentioned
$BX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BXBullishLow
01

Why it matters

The only new information is the disclosed open-market purchase size, price range, and post-transaction holdings; it does not change BX’s fundamentals in the text.

02

Market read

Traders may note mild sentiment from director buying, but there is no fundamental catalyst or guidance change disclosed.

03

What to watch

The article notes no pre-arranged 10b5-1 plan, but it still provides no rationale for the purchase or any follow-on buying/selling pattern.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

The article is a SEC Form 4 insider transaction disclosure for Blackstone director Porat Ruth.

Company-level read

Ticker impact

$BXBullishMedium confidence
Context

Porat Ruth, a Blackstone director, filed a Form 4 showing an open-market purchase of 371 shares at about $137.17 on 2026-08-10.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine insider transaction with modest size relative to BX’s market cap, and it does not include new business guidance, contracts, or regulatory outcomes.

Market effects

No clear sector read-through; insider buys are generally idiosyncratic.

None indicated.

None indicated.

Counterpoint

Director buys can be driven by diversification, liquidity planning, or pre-existing compensation mechanics rather than a strong bullish thesis.

Key entities

  • Blackstone Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Porat Ruth

    Director who purchased 371 shares of BX on 2026-08-10.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BXMedAI 8/10

Blackstone Life Sciences announces $455M collaboration with Boston Scientific

Blackstone Life Sciences (BX) and Boston Scientific (BSX) are collaborating on a $455M project to develop the VITALYST heart pump system. This is the first co-funding deal between the two companies. The system aims to treat acute myocardial infarction cardiogenic shock by improving blood flow. BXLS sees potential in the technology to enhance current mechanical circulatory support devices.